Pyxis Oncology (PYXS)
NASDAQ:PYXS
Want to see PYXS full AI Analyst Report?
Top Page
Pyxis Oncology
(NASDAQ:PYXS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▼(-9.64% Downside)
Action:Reiterated
Date:05/27/26
The score is primarily constrained by weak financial performance—large ongoing losses, heavy cash burn, shrinking equity/assets, and revenue that appears non-recurring. Technical indicators are mixed (neutral momentum with some oversold signals but price below key moving averages), while valuation is limited by negative earnings and no dividend support.
Positive Factors
Regulatory alignment & clinical progress
FDA alignment on a planned pivotal MICVO monotherapy trial plus completed Phase 1 expansion enrollment materially reduces regulatory and design uncertainty. Scheduled mid-2026 and H2 data readouts create clear development milestones that can validate the program and de-risk pathway to registrational studies.
Negative Factors
High and persistent cash burn
Sustained negative operating and free cash flow around -$67M TTM signals heavy ongoing cash consumption to advance trials. Over a 2–6 month horizon this necessitates external financing or program cuts, raising dilution risk and forcing prioritization that can delay or reduce the scope of development activities.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory alignment & clinical progress
FDA alignment on a planned pivotal MICVO monotherapy trial plus completed Phase 1 expansion enrollment materially reduces regulatory and design uncertainty. Scheduled mid-2026 and H2 data readouts create clear development milestones that can validate the program and de-risk pathway to registrational studies.
Read all positive factors
Pyxis Oncology Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Shows how the company’s sales are split across business lines and markets—such as product sales, licensing and milestone payments, services or partnerships, and geographic regions—highlighting which areas drive growth and cash flow. A heavy concentration in one product or partner raises revenue risk and volatility, while diversified or recurring streams point to more stable, scalable upside. For smaller or clinical-stage biotech firms, low commercial revenue and reliance on milestone/license payments warn that future earnings depend on clinical progress and deal-making.
Data provided by:
The Fly
The FlyPyxis Oncology (PYXS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$111.51M
Dividend YieldN/A
Average Volume (3M)757.02K
Price to Earnings (P/E)―
Beta (1Y)1.44
Revenue GrowthN/A
EPS Growth17.43%
CountryUS
Employees44
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.31
Shares Outstanding63,355,480
10 Day Avg. Volume789,983
30 Day Avg. Volume757,017
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue9.02
Enterprise Value/Gross Profit9.04
Enterprise Value/Ebitda-1.65
Forecast
1Y Price Target
$6.50Price Target Upside291.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$43.75K
Pyxis Oncology Business Overview & Revenue Model
Company Description
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobu...
How the Company Makes Money
Pyxis Oncology is a clinical-stage company and does not have a disclosed commercial product portfolio generating recurring product sales. As a result, revenue—when present—is primarily driven by non-recurring or development-stage sources rather th...
Pyxis Oncology Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.86M | 13.86M | 16.15M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 13.83M | 11.47M | 15.67M | 0.00 | 0.00 | 0.00 |
| EBITDA | -75.93M | -73.72M | -65.51M | -71.86M | -120.01M | -75.33M |
| Net Income | -81.73M | -79.62M | -77.33M | -73.79M | -120.72M | -75.97M |
Balance Sheet | ||||||
| Total Assets | 64.30M | 91.52M | 157.18M | 173.73M | 211.38M | 280.02M |
| Cash, Cash Equivalents and Short-Term Investments | 42.49M | 66.86M | 126.93M | 119.30M | 179.29M | 274.74M |
| Total Debt | 18.26M | 18.67M | 20.20M | 21.33M | 18.92M | 165.00K |
| Total Liabilities | 33.03M | 38.11M | 36.43M | 48.02M | 50.55M | 18.71M |
| Stockholders Equity | 31.27M | 53.41M | 120.75M | 125.70M | 160.82M | 261.31M |
Cash Flow | ||||||
| Free Cash Flow | -66.98M | -63.51M | -57.91M | -77.44M | -95.73M | -35.87M |
| Operating Cash Flow | -66.97M | -63.50M | -57.67M | -70.71M | -89.33M | -35.33M |
| Investing Cash Flow | 59.41M | 58.86M | 8.15M | -104.85M | -6.40M | -590.00K |
| Financing Cash Flow | 569.00K | 594.00K | 59.33M | 5.93M | 183.00K | 304.04M |
Pyxis Oncology Technical Analysis
Neutral
1.66
Price Trends
1.85
Negative
1.66
Positive
2.29
Negative
Market Momentum
-0.07
Positive
46.92
Neutral
41.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PYXS, the sentiment is Neutral. The current price of 1.66 is below the 20-day moving average (MA) of 1.81, below the 50-day MA of 1.85, and below the 200-day MA of 2.29, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 46.92 is Neutral, neither overbought nor oversold. The STOCH value of 41.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PYXS.
Pyxis Oncology Risk Analysis
Pyxis Oncology disclosed 77 risk factors in its most recent earnings report. Pyxis Oncology reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pyxis Oncology Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $283.43M | ― | -2748.16% | ― | ― | 43.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $284.09M | -9.23 | -147.78% | ― | ― | -16.88% | |
45 Neutral | $204.62M | ― | -30.90% | ― | ― | 10.70% | |
44 Neutral | $111.51M | -1.37 | -135.60% | ― | ― | 17.43% | |
44 Neutral | $84.59M | -1.88 | -196.72% | ― | ― | 74.83% |
* Healthcare Sector Average
PYXS
Pyxis Oncology
1.76
0.55
45.45%
NKTX
Nkarta
2.86
0.97
51.32%
GLSI
Greenwich LifeSciences
24.06
14.86
161.52%
ELTX
Elicio Therapeutics
14.85
7.15
92.73%
BMEA
Biomea Fusion
1.17
-1.46
-55.51%
NVCT
Nuvectis Pharma
10.71
2.07
23.96%
Pyxis Oncology Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Pyxis Oncology Reports Q4 Results, Advances MICVO Program
Positive
Mar 23, 2026
Pyxis Oncology reported a series of clinical and corporate milestones alongside its fourth quarter and full-year 2025 results, released on March 23, 2026, highlighting progress in its MICVO program for recurrent/metastatic head and neck squamous c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.